Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: A specialty pharmaceutical company focused on infectious diseases. Its lead product, ARAKODA (tafenoquine), is FDA-approved for malaria prevention. The company is currently pivoting to commercialize Arakoda for babesiosis and other indications after suspending a COVID-19 clinical trial in late 2023.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 |
Six Months Ended June 30, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|
| Product Revenues | $124,972 | $230,646 | $76,704 |
| Total Net Revenue | $124,972 | $241,435 | $76,704 |
| Gross Profit | $35,408 | $86,434 | $(180,393) |
| Gross Margin % | 28.33% | 35.80% | (235.18%) |
| Net Loss (Attributable to 60P) | $(4,172,755) | $(3,742,285) | $(5,936,616) |
| Net Loss Per Share (Basic/Diluted) | $(4.23) | $(4.28) | $(30.44) |
| Cash and Equivalents (End of Period) | $1,576,602 (as of June 30, 2024) | ||
| Total Debt (SBA EIDL) | $157,442 (Current: $8,772; Long-term: $148,670) |
Material Changes vs. Prior Period
- Revenue Growth: Product revenues increased 110% quarter-over-quarter and 201% year-over-year (six months). This growth is driven by increased sales volume in the U.S. civilian supply chain (288% increase in boxes sold Q2 2024 vs Q2 2023) and new sales in Australia.
- Gross Margin Improvement: Gross margin turned positive (28.33% in Q2 2024) compared to a significant loss in the prior year. This is attributed to higher sales volume absorbing fixed costs and a reduction in inventory write-downs for expired goods ($16,684 in Q2 2024 vs $111,220 in Q2 2023).
- Operating Expenses: Total operating expenses surged 534% year-over-year (six months). Research and Development (R&D) expenses increased 947% primarily due to a $2.625 million non-cash share-based compensation expense recognized upon delivery of a report from a vendor (Kentucky Technology, Inc.) and costs related to the new babesiosis clinical trial.
- Non-Operating Income: The company recorded a $1.74 million gain on the change in fair value of derivative liabilities (contingent milestone payments) for the six months ended June 30, 2024, compared to minimal activity in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing includes a "Going Concern" warning. The company has an accumulated deficit of $36.3 million and has not demonstrated the ability to generate sufficient revenue to cover expenses. Management estimates sufficient funds to remain viable through March 31, 2025, based on recent financing and sales growth, but additional capital will likely be required.
- Reverse Stock Split: A 1:12 reverse stock split was approved by shareholders and became effective on August 12, 2024, to regain compliance with Nasdaq listing requirements (minimum $1.00 bid price). All share and per-share data in the filing have been retroactively adjusted.
- Recent Financing: In January 2024, the company raised approximately $1.9 million via a public offering. Subsequently, between July and August 2024, the company sold 677,819 shares under an At-The-Market (ATM) agreement, raising an additional ~$2.0 million.
- Clinical Progress: The company initiated a clinical trial for tafenoquine in treating acute babesiosis, with the first patient enrolled in June 2024. Agreements were signed with Yale University and Rhode Island Hospital in July 2024.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of full-time in-house personnel with technical knowledge for complex transactions and inadequate segregation of duties.
Investor Verification Checklist
- Liquidity Runway: Verify the accuracy of the management's projection to remain viable through March 31, 2025, given the high burn rate and reliance on future financing.
- Revenue Concentration: Note that 92-95% of product revenues come from a single U.S. pharmaceutical distributor; assess the risk of concentration.
- Non-Cash Expenses: Review the impact of the $2.625 million share-based compensation expense on R&D, which significantly inflated operating costs for the period.
- Derivative Liability Valuation: Understand the $567,050 derivative liability (contingent milestone payment to Knight Therapeutics) and the assumptions used to value it, as changes in fair value significantly impact net income.
- Nasdaq Compliance: Monitor whether the reverse stock split successfully maintains the stock price above the $1.00 threshold to avoid delisting.